Compound Reference
Semax Research Overview
Last updated:
Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH).
Semax has no approved human medical indication and has not been evaluated by the FDA or any other regulatory body for safety or efficacy in humans. Published research on Semax is overwhelmingly preclinical: conducted in vitro (cell and tissue culture) or in animal models, primarily rodents. We are not aware of well-controlled human clinical trials establishing a therapeutic effect for any condition.
Semax has an extensive published preclinical literature, largely originating from Russian pharmacological research, concentrated in neuroscience models:
- Neuroprotection research — rodent models of cerebral ischemia have been used to study semax in the context of neuroprotective-signaling pathways.
- BDNF-expression research — animal studies have investigated semax's association with brain-derived neurotrophic factor (BDNF) expression.
- Cognitive and behavioral models — rodent behavioral studies have examined semax in the context of learning- and memory-related endpoints.
These are summaries of published research topics, not claims about what this product does, and animal-model findings do not establish an effect in humans. See References below to search the primary literature directly.
Limitations
State of the Evidence
Semax's published literature is concentrated in a specific national research tradition with limited independent replication outside that body of work; rodent neuroprotection and behavioral findings do not establish an equivalent effect in humans.
References
Primary Literature
The links below open a PubMed search for each research topic referenced above, rather than a single citation, so you can review the primary literature directly rather than rely on our summary of it.
All products are intended for laboratory and research purposes only. Not for human or veterinary use. Not a drug. Not for diagnostic or therapeutic use.